Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
67 studies found for:    Blood Transfusion | Open Studies | NIH, U.S. Fed
Show Display Options
Rank Status Study
21 Recruiting Detection and Management of Non‐Compressible Hemorrhage by Vena Cava Ultrasonography
Condition: Major Trauma Patients Brought to Level I Trauma Centers.
Intervention: Device: Ultrasound of inferior vena cava
22 Recruiting Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs
Condition: Immune Tolerance
Intervention: Device: Immune tolerance
23 Recruiting Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Myeloid Leukemia in Remission;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Acute Lymphoblastic Leukemia in Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   RAEB-1;   RAEB-2;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: T Cell-Depleted Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
24 Recruiting Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Condition: ESRD
Intervention: Drug: Immune Tolerance
25 Recruiting Molecular Immunohematology in Ethiopian Sub-Populations
Conditions: Blood Group Antigens;   Blood Grouping and Crossmatching
Intervention:
26 Recruiting Screening for Subjects to Participate in Studies of Blood Disorders
Conditions: Bone Marrow Transplant;   Sickle Cell Disease;   G-CSF
Intervention:
27 Recruiting Alemtuzumab (Campath ) to Treat T-Large Granular Lymphocyte Leukemia
Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
28 Recruiting Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies
Conditions: Cervical Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vulvar Carcinoma;   Uterine Corpus Cancer;   Vulvar Carcinoma;   Peritoneal Neoplasms
Interventions: Other: Palliative Therapy;   Other: Palliative Therapy + idiographic
29 Recruiting Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Graft Versus Host Disease;   Lymphoblastic Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Anemia With Excess Blasts
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
30 Recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
Conditions: HIV Infection;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Plasmablastic Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Follicular Lymphoma;   Stage III Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Biological: Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation
31 Recruiting Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial
Condition: Anemia
Interventions: Procedure: Drawing admission labs from cord blood;   Procedure: Drawing admission labs from infant blood
32 Recruiting Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies
Conditions: Primary T-cell Immunodeficiency Disorders;   Common Variable Immunodeficiency;   Immune System Diseases;   Autoimmune Lymphoproliferative;   Lymphoproliferative Disorders
Interventions: Drug: Immunosuppression Only Conditioning;   Drug: Reduced Intensity Conditioning;   Drug: Myeloablative Conditioning;   Drug: GVHD Prophylaxis;   Procedure: Allo BMT
33 Recruiting Age of Blood in Children in Pediatric Intensive Care Units
Condition: Anemia
Intervention: Biological: Short storage RBC age
34 Recruiting Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Leukemia of Ambiguous Lineage;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Biological: Filgrastim;   Drug: Fludarabine Phosphate
35 Recruiting Control of Major Bleeding After Trauma Study
Conditions: Trauma;   Hemorrhagic Shock
Interventions: Biological: Type AB plasma;   Drug: Crystalloid fluid (standard of care for resuscitation)
36 Recruiting Evaluation of Sickle Cell Liver Disease
Condition: Sickle Cell Disease
Intervention:
37 Recruiting A Randomized Trial of Induction Versus Expectant Management
Condition: Labor and Delivery
Intervention: Procedure: Elective Induction of Labor
38 Recruiting Genetic Studies of Chronic Active Epstein-Barr Disease
Condition: Epstein-Barr Virus Infections
Intervention:
39 Recruiting Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
Condition: Sickle Cell Disease
Interventions: Behavioral: Patient Navigator;   Behavioral: Recruitment into Specialty Care
40 Recruiting Extended Dosing With Eltrombopag for Severe Aplastic Anemia
Condition: Severe Aplastic Anemia (SAA)
Intervention: Drug: Eltrombopag

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years